Perrigo Return on Tangible Equity 2012-2026 | PRGO
Current and historical return on tangible equity values for Perrigo (PRGO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Perrigo Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-12-31 | $-1.42B | $-1.46B | 97.65% |
| 2025-09-30 | $-0.05B | $-1.45B | 3.45% |
| 2025-06-30 | $-0.08B | $-1.50B | 5.28% |
| 2025-03-31 | $-0.18B | $-1.47B | 12.17% |
| 2024-12-31 | $-0.17B | $-1.52B | 11.23% |
| 2024-09-30 | $-0.16B | $-1.60B | 9.93% |
| 2024-06-30 | $-0.12B | $-1.66B | 7.46% |
| 2024-03-31 | $-0.01B | $-1.76B | 0.46% |
| 2023-12-31 | $-0.01B | $-1.81B | 0.72% |
| 2023-09-30 | $-0.01B | $-1.86B | 0.27% |
| 2023-06-30 | $-0.07B | $-1.89B | 3.59% |
| 2023-03-31 | $-0.14B | $-1.92B | 7.34% |
| 2022-12-31 | $-0.14B | $-1.43B | 9.81% |
| 2022-09-30 | $-0.11B | $-0.94B | 11.24% |
| 2022-06-30 | $-0.12B | $-0.49B | 23.67% |
| 2022-03-31 | $-0.11B | $0.03B | -337.98% |
| 2021-12-31 | $-0.07B | $0.05B | -148.39% |
| 2021-09-30 | $-0.25B | $0.06B | -396.88% |
| 2021-06-30 | $-0.35B | $-0.15B | 236.49% |
| 2021-03-31 | $-0.23B | $-0.44B | 53.07% |
| 2020-12-31 | $-0.16B | $-0.78B | 20.96% |
| 2020-09-30 | $-0.01B | $-1.12B | 0.62% |
| 2020-06-30 | $0.24B | $-1.24B | -19.34% |
| 2020-03-31 | $0.19B | $-1.22B | -15.45% |
| 2019-12-31 | $0.15B | $-1.17B | -12.46% |
| 2019-09-30 | $0.25B | $-1.15B | -21.46% |
| 2019-06-30 | $0.09B | $-1.13B | -7.68% |
| 2019-03-31 | $0.11B | $-1.25B | -9.10% |
| 2018-12-31 | $0.13B | $-1.33B | -9.87% |
| 2018-09-30 | $0.12B | $-1.37B | -8.91% |
| 2018-06-30 | $0.24B | $-1.42B | -16.50% |
| 2018-03-31 | $0.13B | $-1.46B | -8.83% |
| 2017-12-31 | $0.12B | $-1.49B | -8.08% |
| 2017-09-30 | $-1.31B | $-2.13B | 61.66% |
| 2017-06-30 | $-2.95B | $-2.88B | 102.51% |
| 2017-03-31 | $-3.41B | $-3.74B | 91.21% |
| 2016-12-31 | $-4.01B | $-4.76B | 84.24% |
| 2016-09-30 | $-2.83B | $-5.09B | 55.59% |
| 2016-06-30 | $-0.98B | $-5.18B | 18.85% |
| 2016-03-31 | $-0.46B | $-5.10B | 9.11% |
| 2015-12-31 | $0.04B | $-3.81B | -1.13% |
| 2015-09-30 | $0.29B | $-2.60B | -11.04% |
| 2015-06-30 | $0.12B | $-1.74B | -7.02% |
| 2014-12-31 | $0.21B | $-1.35B | -15.86% |
| 2014-09-30 | $0.06B | $-1.74B | -3.33% |
| 2013-12-31 | $0.14B | $-0.42B | -32.66% |
| 2013-09-30 | $0.33B | $0.15B | 219.33% |
| 2012-12-31 | $0.33B | $0.31B | 107.19% |
| 2012-09-30 | $0.32B | $0.25B | 129.58% |
| 2011-12-31 | $0.26B | $0.14B | 185.66% |
| 2011-09-30 | $0.25B | $0.15B | 172.32% |
| 2010-12-31 | $0.23B | $0.13B | 175.88% |
| 2010-09-30 | $0.20B | $0.23B | 84.73% |
| 2009-12-31 | $0.16B | $0.45B | 35.29% |
| 2009-09-30 | $0.12B | $0.41B | 30.24% |
| 2008-12-31 | $0.10B | $0.38B | 26.89% |
| 2008-09-30 | $0.11B | $0.40B | 27.77% |
| 2007-12-31 | $0.09B | $0.39B | 21.94% |
| 2007-09-30 | $0.07B | $0.38B | 19.15% |
| 2006-12-31 | $0.06B | $0.35B | 16.83% |
| 2006-09-30 | $0.06B | $0.34B | 18.65% |
| 2005-12-31 | $-0.34B | $0.31B | -110.98% |
| 2005-09-30 | $-0.35B | $0.36B | -96.89% |
| 2004-12-31 | $0.05B | $0.51B | 10.23% |
| 2004-09-30 | $0.07B | $0.49B | 15.03% |
| 2003-12-31 | $0.07B | $0.43B | 16.15% |
| 2003-09-30 | $0.05B | $0.41B | 11.76% |
| 2002-12-31 | $0.05B | $0.38B | 14.29% |
| 2002-09-30 | $0.05B | $0.37B | 14.04% |
| 2001-12-31 | $0.04B | $0.35B | 10.84% |
| 2001-09-30 | $0.02B | $0.35B | 6.92% |
| 2001-03-31 | $0.01B | $0.35B | 4.06% |
| 2000-12-31 | $0.01B | $0.34B | 2.93% |
| 2000-09-30 | $0.02B | $0.34B | 5.90% |
| 2000-06-30 | $0.02B | $0.33B | 5.70% |
| 2000-03-31 | $0.02B | $0.33B | 7.31% |
| 1999-12-31 | $0.03B | $0.32B | 8.72% |
| 1999-09-30 | $0.02B | $0.31B | 7.65% |
| 1999-06-30 | $0.00B | $0.31B | 0.65% |
| 1999-03-31 | $-0.08B | $0.31B | -27.12% |
| 1998-12-31 | $-0.09B | $0.33B | -25.95% |
| 1998-09-30 | $-0.08B | $0.35B | -22.61% |
| 1998-06-30 | $-0.05B | $0.37B | -14.46% |
| 1998-03-31 | $0.05B | $0.38B | 11.79% |
| 1997-12-31 | $0.05B | $0.38B | 12.64% |
| 1997-09-30 | $0.05B | $0.38B | 12.73% |
| 1997-06-30 | $0.05B | $0.37B | 12.47% |
| 1997-03-31 | $0.04B | $0.36B | 11.76% |
| 1996-12-31 | $0.04B | $0.35B | 11.85% |
| 1996-09-30 | $0.04B | $0.34B | 11.63% |
| 1996-06-30 | $0.04B | $0.33B | 12.32% |
| 1996-03-31 | $0.04B | $0.31B | 12.73% |
| 1995-12-31 | $0.04B | $0.30B | 13.18% |
| 1995-09-30 | $0.04B | $0.30B | 13.82% |
| 1995-06-30 | $0.04B | $0.29B | 15.19% |
| 1995-03-31 | $0.05B | $0.28B | 18.09% |
| 1994-12-31 | $0.05B | $0.27B | 19.43% |
| 1994-09-30 | $0.06B | $0.26B | 21.30% |
| 1994-06-30 | $0.06B | $0.24B | 22.66% |
| 1994-03-31 | $0.05B | $0.23B | 23.76% |
| 1993-12-31 | $0.05B | $0.21B | 24.53% |
| 1993-09-30 | $0.05B | $0.20B | 24.78% |
| 1993-06-30 | $0.04B | $0.18B | 23.98% |
| 1993-03-31 | $0.04B | $0.17B | 24.05% |
| 1992-12-31 | $0.04B | $0.16B | 23.97% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $1.495B | $4.253B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |